Results 141 to 150 of about 4,770 (180)

Cutaneous Adverse Effects of Elexacaftor-Tezacaftor-Ivacaftor: A Single Center Cohort Study on Acne Severity in Adults With Cystic Fibrosis. [PDF]

J Cosmet Dermatol
Smith AD, Lyons CE, Somerville L, Flowers RH, Kaplan E, Albon D.   +5 more
europepmc   +1 more source

Modulation of host inflammatory pathways by <i>Pseudomonas aeruginosa</i> extracellular vesicles in cystic fibrosis: impact of pulmonary exacerbation and elexacaftor-tezacaftor-ivacaftor treatment. [PDF]

Front Immunol
Said M, Burrell A, Harmon B, Krohmaly KI, Mazur M, Solomon GM, Hahn A.   +6 more
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis. [PDF]

Pediatr Pulmonol
Trost SU, Harindhanavudhi T, Wang Q, Ankireddypalli A, Simrah A, Avula S, Moheet A.   +6 more
europepmc   +1 more source

Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis. [PDF]

Eur Respir J
Halle O, Graeber SY, Kontsendorn J, Kessemeier C, Falke JN, Schwabe J, Schütz K, Pallenberg ST, Dalferth R, Grychtol R, Ringshausen FC, Stahl M, Thee S, Roehmel JF, Syunyaeva Z, Duerr J, Chung J, Hirtz S, Uselmann T, Kühbandner I, Rückes-Nilges C, Bagheri-Pothoff A, Barth S, Schaub B, Brinkmann F, Weber S, van Koningsbruggen-Rietschel S, Abdo M, Weckmann M, Widder S, Hansen G, Tümmler B, Sommerburg O, Naehrlich L, Mall MA, Dittrich AM.   +35 more
europepmc   +1 more source

Aging Gracefully: Does Elexacaftor/Tezacaftor/Ivacaftor Safety and Efficacy Stand the Test of Time? [PDF]

Am J Respir Crit Care Med
Wilson G, Hughes D.
europepmc   +1 more source

Delayed-onset drug-induced liver injury in a cystic fibrosis patient on long-term elexacaftor/ivacaftor/tezacaftor therapy: A case report and literature review. [PDF]

Can Liver J
Alenezi AF, Sachar Y, Sandhu A.
europepmc   +1 more source

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor-Mediated Drug-Induced Liver Injury Using a Liver-On-Chip Model. [PDF]

Clin Transl Sci
Shi A, Agarwal P, Liu ZX, Beringer PM.
europepmc   +1 more source

Scedosporium infection as a late complication after start of elexacaftor/tezacaftor/ivacaftor: two case reports. [PDF]

Respir Med Case Rep
van Mourik P, van der Hout EC, Luijk HD, Hofland RW, Bruns AHW, Heijerman HGM, Bronsveld I.   +6 more
europepmc   +1 more source

Real-World Outcomes of Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis. [PDF]

Ann Am Thorac Soc
Perrem L, McNally P.
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Muscle Composition in Cystic Fibrosis: An AI-Assisted Chest CT-Based Body Composition Analysis. [PDF]

Med Sci (Basel)
Welsner M, Stehling F, Gruber W, Westhölter D, Sutharsan S, Taube C, Büscher E, Nensa F, Zensen S, Umutlu L, Forsting M, Haubold J, Salhöfer L, Holtkamp M, Kohnke J, Hosch R, Opitz M.   +16 more
europepmc   +1 more source